Theralase Technologies Inc. V.TLT

CR at 450

[Oilminerdeluxe]

Perhaps not the brightest question, but I do not claim to be smart. Once we have enough patients done, what is the lowest CR percentage TLT should have to be approved for BTD and AA? Any thoughts?

[Rumpl3StiltSkin]

Hmm, 1433 isn't really a drug per se. Since it works at the cellular level it should work 100% It is a bit of a puzzle of why the %s are as low as they are currently. It has more to do with the patients and the Clinicians that 1433, IMO. To me it means keep trying, if 1433 didn't work the first time give it another go. I hope Docs will understand that. For this Study 2? to be successful I

[Oilminerdeluxe]

Thanks. Hope we get there.

[Rumpl3StiltSkin]

It is also the inexact nature of the delivery system for NMIBC. Once TLT gets 1433/Rutherrin into solid tumors the PR-CR %s will be a lot higher, IMO...  

[CancerSlayer]

  For deeper solid tumors, the greater challenge will not be with drug delivery, but will be with trying to achieve precise/optimal light or energy delivery in whatever form it's given.  The drug has been proven to perform exceedingly well in multiple cancers preclinically, including in an NSCLC cell line as demonstrated by Roswell Park.  Those TLD-1433 preclinical studies

[Rumpl3StiltSkin]

Yes, and It would be very nice if TLT could demonstrate PDC activation using XRays... Would certainly simplify delivery for the solid tumors. Wonder when they will complete their GLP for this?

[fredgoodwinson]

Well that would be the Toxicity study for Rutherrin which despite its` clear superiority over TLD-1433 as calibrated and set out by Dr.Lilge in an AGM lecture over 5 years` ago they have progessively rowed back from over the past few years. They did mention earlier this year that they might commence the Study in Q4 2022 but given the history of delays to date we can`t rely on this as a timeline.

[99942Apophis]

fredgoodwinson wrote Well that would be the Toxicity study for Rutherrin which despite its` clear superiority over TLD-1433 as calibrated and set out by Dr.Lilge in an AGM lecture over 5 years` ago they have progessively rowed back from over the past few years. They did mention earlier this year that they might commence the Study in Q4 2022 but given the history of delays to date we can`t rely on

[StevenBirch]

I think they are focused strictly on NMIBC Phase II right now in terms of keeping us up to date and probably because we are so close. Nothing else has been shown to move the stock price and they have shown that they care more about their business/research than the share price so I am sure there is lots going on behind the scenes and we will know in due time. It's funny how when we don't

[Legit62]

Does anyone know if we will get an August update??? 

[Rumpl3StiltSkin]

We Might hear something on the Covid vax in Aug. I disagree with Steven B. I think the last time we got some solid news on Covid, it moved stock up significantly. Should do so again and more this time if it is good/great news!

[StevenBirch]

Sorry I wasn't really considering Covid, I agree.

[Longholder99]

Sadly covid isnt going anywhere. I know as I just got through a bout of it with this new variant and its no picnic. What doesn't kill you, mutates and tries to kill you again is basically the way its going to be unless something changes. If Theralase has a non immuno and therefore novel non variant dependant approach to neutralizing covid the markets may totally walk this up. It may have a

[thadeush]

Agree. A way to neutralize COVID will be massive, especially when the effect of long COVID starts to have a serious impact on the economy and healthcare system (though no one seems to care about the latter). Thousands are already suffering though, like COVID, the media is not interested in covering it. Airports are a bit chaotic (b/c of COVID) after all. https://www.theguardian.com/society/2022

[consultant99]

There is a lot of potential - I 100% totally agree with you. It might not be enough to just be able to make a vaccine that works but how this novel approach compares to existing vaccines. Will it be quicker to make? Will it be cheaper to make store and transport? Will it have greater efficacy? Will it be safer? How adaptable to other viruses? NVAX share price went from less than $5/share to over

[ScienceFirst]

Consultant99 ... We already had/have some answers from NML so far. Will it be quicker to make? sounds like yes as per a comment by Dr. Kobasa Will it be cheaper to make store and transport?  sounds like yes Will it have greater efficacy? sounds like yes, given it destroys the virus envelopes Will it be safer? yes given the low dose (nano molecular dose) hinted by Dr. Coombs and Dr

[consultant99]

Good to know ScienceFirst. Unfortunately heresay and piecing together information is not going to get the share price higher. Provable results matter which is why the share price languishes. We need more buyers to get the share price higher. When the company applies for BTD we will see a share price spike. If the vaccine animal trials are successful we will see a share price spike. With Roger

[ScienceFirst]

Consultant ... I totally agree with you.   We are at crossroads of having a larger pool of data on the NMIBC side that will help us where we stand against competition. And NML update on the COVID-19 indication is expected to provide clearer details by Q4.  

[ScienceFirst]

Legit62... By August 31

[CancerSlayer]

Agree....the success-limiting factor is more likely related to the patient/practioner, not the drug/ACT.  The fact that we are dealing with older bladders likely has a lot to do with the "lower-than-expected" CR percentages imo.  There is likely a greater potential for poor tissue uptake of any agent that is administered into an older vs younger bladder.  Older bladders